Anticoagulation Therapy Market is expected to gain market growth in the forecast period of 2021 to 2028.
Data Bridge Market Research analyses the market to account to grow at a CAGR of 8.80% in the above mentioned forecast period.
- The Anticoagulation Therapy Market Scope and Size
An influential Anticoagulation Therapy Market report is a total overview of the market that covers various aspects of product definition, market segmentation based on various parameters, and the existing vendor landscape. This market research report is a scrupulous analysis of current scenario of the market, which covers several market dynamics. This report motivates clients to seek new business ventures and evolve better.
Get PDF Sample and More Information @ https://www.databridgemarketresearch.com/request-a-sample/?dbmr=global-anticoagulation-therapy-market
This Anticoagulation Therapy Market study also estimates the market status, market share, growth rate, sales volume, future trends, market drivers, market restraints, revenue generation, opportunities and challenges, risks and entry barriers, sales channels, and distributors.
- Market Analysis and Insights - Global Anticoagulation Therapy Market
Global Anticoagulation Therapy Market research report identifies and analyses the up-and-coming trends along with major drivers, restraints, challenges and opportunities in the market for Healthcare industry.
This market research report deals with an array of important market related aspects which can be listed as follows; market size estimations, company and market best practices, entry level strategies, market dynamics, competitive landscaping and benchmarking, roadmap analysis, and in-depth benchmarking of vendor offerings.
- Anticoagulation Therapy Market Country Level Analysis
U.S., Canada, Mexico, Germany, Italy, U.K., France, Spain, Netherland, Belgium, Switzerland, Turkey, Russia, Rest of Europe, Japan, China, India, South Korea, Australia, Singapore, Malaysia, Thailand, Indonesia, Philippines, Rest of Asia- Pacific, Brazil, Argentina, Rest of South America, South Africa, Saudi Arabia, UAE, Egypt, Israel, Rest of Middle East & Africa)
Complete Report is Available @ https://www.databridgemarketresearch.com/reports/global-anticoagulation-therapy-market
Anticoagulation Therapy is the most appropriate, realistic and admirable market research report delivered with a supreme devotion and comprehension of business needs.
- Key Players Anticoagulation Therapy Market
Hikma Pharmaceuticals PLC, Mylan N.V., Teva Pharmaceutical Industries Ltd., Novartis AG, Eisai Co., Ltd., Pfizer Inc., Sanofi, F. Hoffmann-La Roche Ltd, Fresenius Kabi AG, Aspen Holdings, Shanghai Fosun Pharmaceutical（Group）Co., Ltd among other domestic and global players
- MAJOR TOC OF THE REPORT
Chapter One: Anticoagulation Therapy Machine Market Overview
Chapter Two: Manufacturers Profiles
Chapter Three: Anticoagulation Therapy Machine Market Competition, by Players
Chapter Four: Anticoagulation Therapy Machine Market Size by Regions
Chapter Five: Anticoagulation Therapy Machine Market Revenue by Countries
Chapter Six: Anticoagulation Therapy Machine Market Revenue by Type
Chapter Seven: Anticoagulation Therapy Machine Market Revenue by Application
Chapter Eight: Anticoagulation Therapy Machine Market Revenue by Industries
Chapter Nine: Anticoagulation Therapy Machine Market Revenue by Deployment Model
Chapter Ten: Anticoagulation Therapy Machine Market Revenue by End User
Get TOC Details: https://www.databridgemarketresearch.com/toc/?dbmr=global-anticoagulation-therapy-market
Browse Related Report:
Antisense and RNAi Therapeutics Market
Batten Disease Treatment Market
About Us:
Data Bridge Market Research set forth itself as an unconventional and neoteric Market research and consulting firm with unparalleled level of resilience and integrated approaches. We are determined to unearth the best market opportunities and foster efficient information for your business to thrive in the market. Data Bridge Market Research provides appropriate solutions to the complex business challenges and initiates an effortless decision-making process.
Contact:
Data Bridge Market Research
Tel: +1-888-387-2818
Email: [email protected]
High cost of NOACs and requirement of significant investments in the development of anticoagulation drugs are the major factors restraining the growth of this market.
In addition, the growth in the anticoagulation clinics market is primarily driven by the increasing prevalence of cardiovascular diseases & blood disorders, high level of medication adherence associated with clinics, and rising aging population.Major Growth Drivers:The market is segmented into products (anticoagulation drugs and PT/INR testing devices) and anticoagulation clinics.
Major players in the market were identified through secondary sources; directories; databases such as Hoovers, Bloomberg Businessweek, Factiva, and OneSource, journals and their market revenues were determined through primary and secondary research.Download PDF Brochure: https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=114158575Based on drug type, the anticoagulation therapy market for drugs is segmented into NOACs, warfarin (VKA), and other drugs.
Due to the better safety and efficacy of NOACs as compared to traditional therapies, the adoption of NOACs is higher as compared to traditional drugs.The anticoagulation therapy market for PT/INR testing devices is segmented into in-office testing devices and home testing devices.
The large share of this segment is mainly attributed to the large number of patients opting for in-office testing services.The anticoagulation therapy market for clinics is segmented on the basis of type of services and clinics.
The types of clinics include hospital associated clinics, independent clinics, and pharmacy-based clinics while the types of services include testing services and consulting services.
The US anticoagulation therapy market is projected to reach USD 27.83 Billion by 2022 from USD 17.25 Billion in 2016, at a CAGR of 8.5%.
The growth in the anticoagulation drugs market is primarily driven by the rising incidence of venous thromboembolism, atrial fibrillation, and stroke; long-term administration and high volume of recurring sales of anticoagulation drugs; and increasing demand for novel oral anticoagulants (NOACs).Industry Segmentation:In this report, the US anticoagulation therapy market is segmented on the basis of products and clinics.
On the basis of products, the market is segmented into anticoagulation drugs and PT/INR testing devices.Download PDF Brochure@ https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=114158575Based on drug type, the anticoagulation therapy market for drugs is segmented into NOACs, warfarin (VKA), and other drugs.
In 2016, the NOACs segment dominated the US anticoagulation therapy market for drugs.
Due to the better safety and efficacy of NOACs as compared to traditional therapies, the adoption of NOACs is higher as compared to traditional drugs.The anticoagulation therapy market for PT/INR testing devices is segmented into in-office testing devices and home testing devices.
The large share of this segment is mainly attributed to the large number of patients opting for in-office testing services.The anticoagulation therapy market for clinics is segmented on the basis of type of services and clinics.
Market Analysis and Insight: Europe Anticoagulation Therapy MarketEurope Anticoagulation Therapy Market By Treatment (Deep Vein Thrombosis (DVT), Pulmonary Embolism (PE), Arterial Thromboembolism (AT), Stroke, Others), Therapeutic Class (Novel Oral Anticoagulants (NOAC), Heparin, Vitamin K Antagonists, Others), Drug Type (Bivalirudin, Dabigatran , Edoxaban, Betrixaban, Rivaroxaban , Apixaban, Enoxaparin, Dalteparin, Others), Route of Administration (Oral, Parenteral), Therapeutic Area (Cardiovascular, Respiratory, Oncology, Nephrology, CNS, Others), Procedure (Pre-Surgical Procedures, Post-Surgical Procedures, Kidney Dialysis, Heart Valve Replacement), Type (Generics, Branded), End User (Hospitals, Clinics, Homecare, Ambulatory Surgical Centres, Others), Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies), Country (Germany, France, U.K., Italy, Spain, Russia, Turkey, Belgium, Netherlands, Switzerland, Rest of Europe) – Industry Trends and Forecast to 2026Anticoagulation therapy is a medication used in prevention of blood clots formation and to uphold blood vessels open.
Anticoagulants are usually called as blood thinners but in reality it do not thin the blood but only helps to prevent or to reduce blood clot formation/thrombi.
There are various anticoagulants available in the market such as vitamin K antagonists, heparin and novel oral anticoagulation which is used for prophylaxis/treatment of various thromboembolic disorders, such as heart attack (myocardial infarction), stroke and deep venous thrombosis (DVT).Europe anticoagulation therapy market is projected to register a substantial CAGR in the forecast period of 2019 to 2026.Get a Sample Copy of report @ https://www.databridgemarketresearch.com/request-a-sample/?dbmr=europe-anticoagulation-therapy-marketSegmentation: Europe Anticoagulation Therapy MarketEurope anticoagulation therapy market is segmented into nine notable segments which are treatment, therapeutic class, drug type, route of administration, therapeutic area, procedure, type, end user and distribution channel.On the basis of treatment, the market is segmented into deep vein thrombosis (DVT), pulmonary embolism (PE), arterial thromboembolism (AT), stroke and othersOn the basis of therapeutic class, the market is segmented into novel oral anticoagulation (NOAC), heparin, vitamin k antagonists and othersOn the basis of drug type, the market is segmented into bivalirudin, dabigatran, edoxaban, betrixaban, rivaroxaban, apixaban, enoxaparin, delteparin and othersOn the basis of route of administration, the market is segmented into oral and injectableOn the basis of therapeutic area, the market is segmented into cardiovascular diseases, oncology, respiratory, nephrology, CNS and othersOn the basis of procedure, the market is segmented into pre-surgical procedures, post-surgical procedures, kidney dialysis and heart valve replacementOn the basis of type, the market is segmented into generics and brandedOn the basis of end user, the market is segmented into hospitals, clinics, homecare, ambulatory surgical centers and othersOn the basis of distribution channel, the market is segmented into hospital pharmacy, retail pharmacy and online pharmacyCompetitive Analysis: Europe Anticoagulation Therapy MarketSome of the major players operating in the Europe anticoagulation therapy market are Hikma Pharmaceuticals PLC, Mylan N.V., Teva Pharmaceutical Industries Ltd., Novartis AG, Eisai Co., Ltd., Pfizer Inc., Sanofi, F. Hoffmann-La Roche Ltd, Fresenius Kabi AG, Aspen Holdings, Shanghai Fosun Pharmaceutical（Group）Co., Ltd. , Cipla Inc, Johnson & Johnson Services, Inc., Bayer AG, Boehringer Ingelheim International GmbH, Bristol-Myers Squibb Company, DAIICHI SANKYO COMPANY, LIMITED, Eagle Pharmaceuticals, Inc., Endo Pharmaceuticals Inc, Mitsubishi Tanabe Pharma Corporation, Portola Pharmaceuticals, Inc., Taro Pharmaceutical Industries Ltd., among others.Get Detailed Table of Contents @ https://www.databridgemarketresearch.com/toc/?dbmr=europe-anticoagulation-therapy-marketRecent DevelopmentsIn September 2018, Sanofi announced Health got Canada approval for Lovenox’s (enoxaparin sodium) new indication toprevent thrombus formation in the extra-corporeal circulation during haemodialysis in patients who are having end stage kidney disease (ESKD).
This will attract the potential consumers helping in the growth of the company.In August 2018, Bayer AG received the European Commission (EC) approval for Xarelto (rivaroxaban) 2.5 mg.
It is indicated for reduction of chances of cardiovascular situations such as stroke/ heart attack in patients with chronic coronary artery disease (CAD), cardiovascular (CV) death, and peripheral artery disease (PAD).
This approval will help the company to develop anticoagulant business in European countries.In June 2015, Daiichi Sankyo Company, Limited received the EU approval for LIXIANA (edoxaban).
